UMnyango Wezizwe Zonke

Ngomhlaka-17 kuJulayi, i-Center for Drug Evaluation (CDE) ye-National Medical Products Administration (NMPA) yamemezela ukuthi isicelo sokumaketha se-Trastuzumab Deruxtecan (Enhertu®) sokwelashwa komdlavuza wesisu sesamukelwe ngokusemthethweni yi-NMPA. Lesi sicelo sihlanganisiwe...Funda kabanzi»

Muva nje, i-Ascentage Pharma imemezele ukuthi i-Bcl-2 selective inhibitor lisaftoclax (APG-2575) yayo entsha ivunyelwe yi-National Medical Products Administration (NMPA) yaseShayina ekwelapheni iziguli ezindala ezine-chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)...Funda kabanzi»

Muva nje, i-GenFleet Therapeutics imemezele ukuthi i-Pharmaceutical Administration Bureau (ISAF) ye-Macau Special Administrative Region yaseShayina ivumile i-Dupert® (fulzerasib, GFH925/IBI351) yokwelapha iziguli ezinomdlavuza wamaphaphu ongeyona encane (NSCLC) othuthukisiwe one-KRAS G12C mutati...Funda kabanzi»

Ngomhlaka-30 Juni, i-Avistone's inhibitor ye-MET eyenziwe ngokuzimela i-Vebreltinib yathola imvume enemibandela evela ku-National Medical Products Administration (NMPA) yaseShayina yokwelapha iziguli ezinomdlavuza wamaphaphu ongeyona iseli encane (NSCLC) othuthuke endaweni noma osakazeke kakhulu one-MET amplifies...Funda kabanzi»

Ngomhlaka-30 Juni 2025, i-HUTCHMED imemezela ukuthi i-New Drug Application (NDA) yokuhlanganiswa kwe-ORPATHYS (savolitinib) kanye ne-TAGRISSO (osimertinib) ivunyelwe yi-China National Medical Products Administration (NMPA) yokwelapha iziguli ezine-metastasis ethuthukisiwe endaweni noma...Funda kabanzi»

Ngomhlaka-30 Juni, iwebhusayithi esemthethweni ye-National Medical Products Administration (NMPA) yamemezela ukuthi i-Anlotinib, umuthi omusha weKlasi 1 owakhiwe yiChia Tai Tianqing, uthole imvume yesibonakaliso esisha eShayina: ukwelashwa okuhlanganisiwe ne-chemotherapy yokwelashwa kokuqala kweziguli ...Funda kabanzi»

Ngomhlaka-26 Juni 2025, i-CARsgen imemezela ukuthi i-National Medical Products Administration (NMPA) yaseShayina yamukele i-New Drug Application (NDA) ye-satricabtagene autoleucel (“satri-cel”, CT041) (umkhiqizo we-CAR T-cell owuhlobo lwe-autologous ngokumelene ne-protein Claudin18.2) wokwelapha i-Claudi...Funda kabanzi»

Ngomhlaka-19 Juni, i-Center for Drug Evaluation (CDE) ye-National Medical Products Administration (NMPA) yamemezela ukuthi umjovo we-LM-108 we-Livzon Pharmaceutical uphakanyiswe ukuthi ufakwe ekwakhiweni kokwelashwa okuphumelelayo. Ukuhlanganiswa komjovo we-antibody we-Kefeqibai monoclonal (LM-1...Funda kabanzi»

Ngomhlaka-19 Juni, i-Center for Drug Evaluation (CDE) ye-National Medical Products Administration (NMPA) yamemezela ukuthi i-IBI343 ye-Innovent Biologics iphakanyisiwe ukuthi ifakwe ohlelweni lokukhetha ukwelashwa okuphumelelayo, oluhloselwe ukwelashwa kwe-pan ethuthukisiwe noma esakazeke endaweni...Funda kabanzi»

Ngomhlaka-6 kuNhlangulana, iphephabhuku lezokwelapha lamazwe ngamazwe i-Journal of Hematology & Oncology lashicilela imiphumela yocwaningo lwesigaba sokuqala/sesibili (KL264-01/MK-2870-001) lwe-TROP2 ADC sacituzumab tirumotecan (sac-TMT) entsha njengokwelashwa okukodwa kwamathumba aqinile angasuswa endaweni noma asakazeke kalula angamelani nomdlavuza...Funda kabanzi»

Ngomhlaka-10 Juni, i-Center for Drug Evaluation (CDE) ye-National Medical Products Administration (NMPA) yamemezela ukuthi i-Trastuzumab Deruxtecan (T-DXd, DS-8201a) ihlongozwa ukuthi inikezwe isibuyekezo esibalulekile sokwelashwa kweziguli ezindala ezine-HER2-positive gastric osteoarthritis esethuthukile noma esakazekile endaweni...Funda kabanzi»

Muva nje, i-Merck & Co., Inc. (Merck) imemezele ukuthi i-PD-1 inhibitor yayo, i-pembrolizumab, ivunyiwe yi-National Medical Products Administration (NMPA) yaseShayina ukuze isetshenziswe kanye ne-lenvatinib kanye ne-transarterial chemoembolization (TACE) ekwelapheni iziguli ezine-unresect...Funda kabanzi»